Neurocrine Biosciences NBIX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $197.9M+28.8% | $153.7M-26.6% | $209.5M+94.9% | $107.5M+1,261% | $7.9M-92.3% | ||
| $7.2M+12.5% | $6.4M-4.5% | $6.7M+6.3% | $6.3M-4.5% | $6.6M+6.5% | ||
| $57.2M-2.4% | $58.6M+9.1% | $53.7M+1.7% | $52.8M0.0% | $52.8M-20.5% | ||
| -$61.1M-227% | $48.2M-71.4% | $168.3M+550% | -$37.4M-173% | -$13.7M+56.2% | ||
| $28.6M— | —— | —— | —— | $0— | ||
| $81.4M— | —— | $132.3M+66.0% | $79.7M+116% | $36.9M— | ||
| -$14.3M-119% | $76.5M+37.1% | $55.8M+80.6% | $30.9M+1,130% | -$3M-104% | ||
| $0— | —— | $200K— | —— | $700K+600% | ||
| $119.8M— | —— | —— | —— | $15.4M-72.1% | ||
| $100K-90.9% | $1.1M+10.0% | $1M0.0% | $1M0.0% | $1M+11.1% | ||
| $25.3M— | —— | $30.6M+557% | -$6.7M+78.1% | -$30.6M-1,511% | ||
| $2.7M— | —— | $6.6M-7.0% | $7.1M-1.4% | $7.2M— | ||
| $145.8M-62.5% | $388.4M+70.7% | $227.5M+123% | $102M+57.4% | $64.8M-73.3% | ||
| $9.1M— | $0-100% | $13.2M+5.6% | $12.5M+16.8% | $10.7M+46.6% | ||
| $819.5M+154% | $323M-20.9% | $408.5M+29.6% | $315.1M+15.3% | $273.2M-12.4% | ||
| $63.2M— | —— | —— | —— | $0— | ||
| -$506.2M-857% | -$52.9M+73.1% | -$196.7M-578% | -$29M-304% | $14.2M+121% | ||
| $54M— | —— | —— | $17.7M-88.2% | $150M-50.0% | ||
| $23.6M-36.7% | $37.3M-18.2% | $45.6M+217% | $14.4M-55.1% | $32.1M+221% | ||
| $55.7M— | —— | —— | —— | $0— | ||
| -$86.1M— | —— | —— | -$3.3M+97.2% | -$117.9M+59.3% | ||
| -$446.5M-220% | $372.8M+389% | $76.2M+9.0% | $69.9M+280% | -$38.9M+66.5% | ||
| $300K-96.2% | $7.8M+609% | $1.1M-98.5% | $71.9M+11,883% | $600K-99.2% | ||
| $1.3M-35.0% | $2M-25.9% | $2.7M-20.6% | $3.4M-26.1% | $4.6M-17.9% | ||
| $100K-90.9% | $1.1M+10.0% | $1M0.0% | $1M0.0% | $1M+11.1% | ||
| $2.7M— | —— | $6.6M-7.0% | $7.1M-1.4% | $7.2M— | ||
| —— | $6.7M0.0% | $6.7M0.0% | $6.7M0.0% | $6.7M+158% | ||
| $259.2M-3.2% | $267.7M+19.0% | $225M-24.6% | $298.6M+0.2% | $298.1M+18.9% | ||
| $1.4M-12.5% | $1.6M— | —— | —— | $2.7M+92.9% | ||
| $136.7M-65.0% | $390.8M+82.4% | $214.3M+139% | $89.5M+65.4% | $54.1M-77.0% | ||
| $136.7M-65.0% | $390.8M+82.4% | $214.3M+139% | $89.5M+65.4% | $54.1M-77.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Neurocrine Biosciences generate?
- Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
- What is Neurocrine Biosciences's free cash flow?
- After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
- Where does Neurocrine Biosciences's cash flow data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
